Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
IPO Year: 2000
Exchange: NASDAQ
Website: illumina.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | $130.00 → $90.00 | Neutral | Citigroup |
| 2/28/2025 | $100.00 | Buy → Hold | HSBC Securities |
| 2/10/2025 | $130.00 → $100.00 | Equal Weight → Underweight | Barclays |
| 2/7/2025 | $177.00 → $140.00 | Buy → Hold | TD Cowen |
| 12/11/2024 | $190.00 → $165.00 | Buy → Neutral | Citigroup |
| 11/12/2024 | $156.00 | Equal-Weight | Morgan Stanley |
| 10/17/2024 | $180.00 | Hold → Buy | HSBC Securities |
| 8/28/2024 | Hold → Buy | Argus | |
| 8/16/2024 | $120.00 → $154.00 | Neutral → Buy | Daiwa Securities |
| 8/14/2024 | $126.00 → $144.00 | Hold → Buy | TD Cowen |
Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously
HSBC Securities downgraded Illumina from Buy to Hold and set a new price target of $100.00
Barclays downgraded Illumina from Equal Weight to Underweight and set a new price target of $100.00 from $130.00 previously
TD Cowen downgraded Illumina from Buy to Hold and set a new price target of $140.00 from $177.00 previously
Citigroup downgraded Illumina from Buy to Neutral and set a new price target of $165.00 from $190.00 previously
Morgan Stanley resumed coverage of Illumina with a rating of Equal-Weight and set a new price target of $156.00
HSBC Securities upgraded Illumina from Hold to Buy and set a new price target of $180.00
Argus upgraded Illumina from Hold to Buy
Daiwa Securities upgraded Illumina from Neutral to Buy and set a new price target of $154.00 from $120.00 previously
TD Cowen upgraded Illumina from Hold to Buy and set a new price target of $144.00 from $126.00 previously
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO, March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO, March 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export sequencing instruments into China. Illumina respects MOFCOM's decision and will continue to comply with all applicable laws and regulations wherever the company operates. Illumina has had a long-standing presence in China, and the company continues to serve its clinical and research customers there. "We remain focused on achieving high-single-digit revenue growth by 2027, while expanding our
Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e
Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability SAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable
Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three years SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the longstanding partners will set the standard for scalable
Broad Institute to collaborate on flagship project tapping Illumina's new spatial technology At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands software portfolio to decode multimodal data with Illumina Connected Multiomics SAN DIEGO, Feb. 19, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial techno
SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference. The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer). Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – (https://illumina-agbt-investor-session-feb-2025.open-exchange.net/) To ens
Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on both a reported and constant currency basisCore Illumina GAAP operating margin of 15.8% and non-GAAP operating margin of 19.7% for Q4 2024; GAAP operating margin of 34.0% and non-GAAP operating margin of 21.3% for fiscal year 2024Core Illumina GAAP diluted earnings per share (EPS) of $0.73 and non-GAAP diluted EPS of $0.95 for Q4 2024; GAAP diluted EPS of $5.61 and non-GAAP diluted EPS of $4.16 for fiscal year 2024Core Illumina cash provided by operations of $1.2 billion and free cash flow of $1.1
SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com. Core Illumina Revenue of approximately $1.10 billion for Q4 2024, up 1% from Q4 2023Revenue of approximately $4.33 billion for 2024, down 2% from 2023 (and on a constant currency basis)GAAP operating margin of approximate
Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery. To optimize analysis of the vast amounts of data involved in multiomic research, Illumina and NVIDIA will combine advancements in AI with multiomic data at scale. Leveraging Illumina's leading sequencing
4 - ILLUMINA, INC. (0001110803) (Issuer)
Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on both a reported and constant currency basisCore Illumina GAAP operating margin of 15.8% and non-GAAP operating margin of 19.7% for Q4 2024; GAAP operating margin of 34.0% and non-GAAP operating margin of 21.3% for fiscal year 2024Core Illumina GAAP diluted earnings per share (EPS) of $0.73 and non-GAAP diluted EPS of $0.95 for Q4 2024; GAAP diluted EPS of $5.61 and non-GAAP diluted EPS of $4.16 for fiscal year 2024Core Illumina cash provided by operations of $1.2 billion and free cash flow of $1.1
SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, February 6, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 6, 2025. Interested parties may access the live webcast via the Investor Info
Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basisCore Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billionRaised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5%Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASD
SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Monday, November 4, 2024. Interested parties may access the live teleconference through the Investor Info section
Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024Core Illumina GAAP operating margin of 40.5% and non-GAAP operating margin of 22.2% for Q2 2024Core Illumina GAAP diluted earnings per share of $0.41 and non-GAAP diluted earnings per share of $1.09 for Q2 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decline 2% to 3% (down 1.5% to 2.5% in constant currency) from 2023Raised Core Illumina non-GAAP operating margin guidance to a range of 20.5% to 21% for fiscal year 2024Introducing guidance for Core Illumina non-GAAP diluted earnings per share in the range of $3.80 to $3.95 for fiscal year 2024O
SAN DIEGO, July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Tuesday, August 6, 2024. Interested parties may access the live teleconference through the Inv
Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO, July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. "The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief techn
"When-issued" trading expected to begin on or about June 12, 2024Record date for distribution of GRAIL shares will be June 13, 2024Distribution date for GRAIL shares anticipated to be June 24, 2024SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024, and has applied to list on Nasdaq as "GRAL." "Today's announcement marks a milestone for Illumina and signals an important step forward for the company, since the divestiture of GRAIL is one of our 2024 priorities," said Jacob Thaysen, CEO of Illumina. "As we prepare to lead the next era
Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis)Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for Q1 2024Reiterating fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately 20%Consolidated revenue of $1.08 billion for Q1 2024, down 1% from Q1 2023 (down 1% on a constant currency basis)GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023Non-GAAP diluted earnings per share of $0.09 for Q1 2024, compared to non-GAA
SAN DIEGO, April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, May 2, 2024. Interested parties may access the live tele
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
144 - ILLUMINA, INC. (0001110803) (Subject)
144 - ILLUMINA, INC. (0001110803) (Subject)
10-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K/A - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10. Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. He brings extensive commercial experience across the healthcare
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments. Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations,
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Chief Executive Officer, effective September 25, 2023. Mr. Thaysen's extensive background and experience in genomics, life sciences, and technology fits closely with Illumina's mission. Since 2018, he has overseen the unit responsible for Agilent's market-l
SAN DIEGO, June 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina's Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior Vice President and General Counsel, has been named interim CEO while the Board of Directors conducts a search for a new CEO. Mr. deSouza will stay on in an advisory capacity until July 31, 2023. Illumina's Board said it is appreciative of Mr. deSouza's contributions and commitment to the company and all of its stakeholders. "We thank Francis for his contributions
Board Chair John Thompson issues letter to Illumina shareholders ahead of the company's Annual Meeting on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time)Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nomineesFor more information, visit www.IlluminaForward.comSAN DIEGO, May 18, 2023 /PRNewswire/ -- Illumina (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter from Board Chair John Thompson. In his letter, Mr. Thompson reiterated the specific steps the company is taking to deliver results consistent with the high standards of performance and value creation expected b
Illumina's director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBCLeading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert EpsteinIcahn's associates bring ZERO relevant experience and ZERO independenceIllumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nomineesAnnual Meeting will be held virtually on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time)For more information, visit www.IlluminaForward.comSAN DIEGO, May 15, 2023 /PRNewswire/ -- Illumina (NASDAQ:ILMN), a glo